SHS_492316 PAGJ CTGT 16025

A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

This is a multi-center, open-label, study to evaluate the safety and efficacy of ublituximab (TG-1101) in combination with TGR-1202 for patients who have progressed on treatment arms previously enrolled in Protocol UTX-TGR-304

Inclusion Criteria:

•Prior treatment in clinical trial UTX-TGR-304
•Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

Exclusion Criteria:

•Patients refractory to ublituximab + TGR-1202
•Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Phase II
NCT02656303
Cancer
Hematologic
John Pagel, M.D.
TG Therapeutics, Inc.
Neil Bailey
  • Swedish Medical Center